MSH2 and metastatic prostate carcinoma: It is now appreciated that approximately 20-25% of metastatic prostate cancers harbor somatic mutations involving DNA-repair genes, primarily homologous-recombination repair genes (e.g. BRCA2, ATM) and, to a lesser extent, mismatch-repair genes (e.g. MSH2, MSH6) [11, 21].